Accueil>>Fz7-21 TFA

Fz7-21 TFA (Synonyms: Ac-LPSDDLEFWCHVMY-NH2 TFA)

Catalog No.GC39383

Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA est un puissant antagoniste peptidique des récepteurs FZD7, se lie sélectivement À la sous-classe FZD7 CRD et modifie la conformation du CRD et l'architecture de son sillon de liaison aux lipides. Les valeurs EC50 sont de 58 et 34 nM pour le FZD7 CRD humain et murin, respectivement. Fz7-21 TFA altère la fonction de FZD7 dans la signalisation Wnt-β-caténine et la fonction des cellules souches dans les organoÏdes intestinaux.

Products are for research use only. Not for human use. We do not sell to patients.

Fz7-21 TFA Chemical Structure

Taille Prix Stock Qté
5mg
261,00 $US
En stock
10mg
414,00 $US
En stock
50mg
1 215,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Fz7-21 TFA ((Ac)-LPSDDLEFWCHVMY-NH2 TFA), a peptide antagonist of Frizzled 7 (FZD 7) receptors, selectively binds to FZD7 CRD subclass. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 impairs Wnt/β-catenin signaling in HEK293 cells stimulated with exogenous WNT3A (IC50=100 nM) or transfected with a construct expressing WNT3A or WNT1. Fz7-21 also blocks WNT3A-mediated stabilization of β-catenin in mouse L cells (IC50=50 nM)[1].

[1]. Nile AH, et al. Publisher Correction: A selective peptide inhibitor of Frizzled 7 receptors disrupts intestinal stem cells. Nat Chem Biol. 2018 Sep;14(9):902.

Avis

Review for Fz7-21 TFA

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Fz7-21 TFA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.